What Coramine Treats: Main Uses and Benefits

Coramine (Nikethamide) is used in situations involving certain distressing symptoms of respiratory depression.

Nikethamide is recognized as a Respiratory Stimulant, which defines its established role in pharmacological applications.

---

Managing Acute Central Respiratory Depression

This domain covers conditions characterized by periods of heightened symptoms related to breathing function. Coramine is applied when appropriate in conditions marked by severely shallow and slowed respiration (hypoventilation), which can lead to insufficient oxygenation and physical signs such as cyanosis. Historically, its key therapeutic use is relevant when supportive symptom management is appropriate during respiratory failure resulting from specific drug overdoses, such as those involving barbiturates and certain narcotics.

“It is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed.”

This supportive therapeutic benefit assists with maintaining functional stability and may help patients cope more steadily with acute respiratory challenges. The supportive action contributes to easing the overall symptom load associated with insufficient ventilation.

---

Supporting Recovery in Critical Clinical Contexts

Coramine is relevant when supportive symptom management is appropriate to stabilize breathing in critical care and recovery scenarios. This includes its use in post-operative recovery to assist surgical patients with maintaining functional stability following the use of general anesthetics. It also helps address symptom clusters like profound drowsiness or stupor when these manifestations are directly linked to the need for respiratory support. This supportive therapeutic benefit contributes to easing the overall symptom load and helps maintain functional stability during difficult episodes of acute physiological stress.

---

Quick Fact: Relief for Shallow Breathing

Regulatory References

1. World Health Organization ATC/DDD Index

Who can and cannot use Coramine?

The official eligibility profile for Coramine (Nikethamide) is strictly defined by regulatory documents, listing specific populations for whom the medicine is contraindicated or restricted.

---

Absolute Contraindications

Coramine must not be used in patients with known hypersensitivity to Nikethamide or a history of central nervous system disorders like Epilepsy and other convulsive disorders. Absolute non-eligibility extends to individuals with Cerebral edema, Cerebrovascular accident, or Head trauma. Cardiovascular contraindications include Severe hypertension and Ischemic heart disease. Other prohibitions include Porphyria, Hyperthyroidism, Acute severe asthma, or physical obstruction of the airway.

---

Age-Group and Conditional Restrictions

Use is absolutely not recommended or contraindicated for pregnant women and nursing mothers due to insufficient safety data. Children and infants are documented as being particularly susceptible to toxic effects, necessitating highly conditional use. Conditional use (caution) is also required for patients with hepatic dysfunction and for older adults with a history of gastrointestinal bleeding or those using anticoagulant medication.

Interactions with other medicines and products

Official regulatory information for Coramine (Nikethamide) identifies several categories of co-administered agents that may enhance the effects of Coramine or increase the risk of specific adverse events.

Interaction Scope

Classification	Examples of Interacting Medicinal Products/Categories
Pharmacodynamic Enhancement	Sympathomimetics, Monoamine Oxidase Inhibitors (MAOIs), Bupropion
Arrhythmia Risk	Certain Anesthetics (e.g., Halothane, Enflurane, Isoflurane)
Effect Masking	Neuromuscular Blockers

Procedural and Contextual Constraints

The co-administration of Coramine with agents such as Sympathomimetics or MAOIs is officially documented to enhance the stimulant effects. Concomitant use with specific Anesthetics increases the potential for cardiac arrhythmias. The product is also documented to mask the effects of Neuromuscular Blockers.

Regulatory documentation establishes constraints requiring a reevaluation of the treatment plan upon the occurrence of a clinically adverse drug interaction. This procedural constraint may lead to the implementation of measures such as adjusting the dose of the agents involved, substituting the interacting drug, or discontinuing Coramine therapy.

How Coramine Works

Coramine's mechanism of action, driven by the active ingredient Nikethamide, is primarily defined by its effects on two key regulatory systems: the central brainstem control and peripheral sensing pathways. This action is one of direct stimulation, increasing the excitability within the central respiratory pathway.

---

Central Excitation of Respiratory Neurons

Nikethamide directly targets and excites the respiratory center located in the medulla oblongata of the brainstem, which is responsible for generating the basic rhythm of breathing. This central action increases the excitability of inspiratory neurons, immediately increasing the strength and frequency of neural signals sent to the breathing muscles. The physiological result is a rapid increase in respiratory rate and tidal volume.

---

Sensitization of Peripheral Chemoreceptors

Concurrently, the drug acts on the peripheral chemoreceptors (in the carotid and aortic bodies) that monitor blood gas levels. By lowering the threshold of these sensors, Nikethamide increases the responsiveness of these chemoreceptors to CO2 and O2 levels. This sensitization augments the signal sent back to the medulla, augmenting the central respiratory signal, resulting in an increased minute ventilation.

Instruction Map: How to use Coramine — Administration Guidelines

The use of Coramine (Nikethamide), classified as a Respiratory Stimulant, involves controlled, short-term intervention using a concentrated solution. The administration focuses on specific protocols designed for clinical application.

---

Administration Scope

Feature	Instruction
Route of administration	Primarily Intravenous (IV) or Subcutaneous (SC) for acute use, although Oral forms have historically been available.
Dosing schedule	Adults: The typical single dose is 1–2 mL (250–500 mg) of the 250 mg/mL injectable solution. For more severe conditions, regimens may extend up to 10 mL total under close medical supervision.
Timing in relation to meals (if applicable)	Not applicable to parenteral administration.
Preparation requirements (if applicable)	The standard injectable concentration is 250 mg/mL (a 25% solution), which is used directly or diluted as needed for IV administration.
Age-group administration rules	Pediatric: Dosing is weight-based, typically 0.1 mL/kg of the injectable solution per dose.
Missed-dose rules	Not applicable; administration is event-driven for acute support rather than scheduled.
Special procedural conditions	Slow IV injection is required to manage administration rate. Administration must occur in a supervised clinical setting by healthcare professionals.

---

Instruction Classifications (High-Level)

Classification	Pattern
Administration method type	Parenteral (Intravenous / Subcutaneous).
Frequency pattern	As-needed/Intermittent (Dose may be repeated every 20 to 30 minutes if required).
Basis of use	Standardized clinical protocols where the product is utilized.
Use-context constraints	Restricted to short-term or acute symptomatic support.

---

Resulting Procedural Structure

Step sequence:

• Determine the weight-adjusted dose (for children) or the 1–2 mL standard adult dose.
• Administer the dose via the intravenous route using a slow injection technique.
• Repeat the injection after 20 to 30 minutes only if necessary, following the specific frequency guidelines.

The instructions involve a structured protocol focusing on the parenteral route and the standardized 250 mg/mL concentration. The procedure is characterized by the need for a slow IV injection and the allowance for repeat administration every 20 to 30 minutes, defining its acute, intermittent usage pattern. This framework, along with weight-based pediatric dosing, establishes the parameters for the drug's use in clinical practice.

Coramine: Research Evidence Overview

Coramine (Nikethamide) was historically studied in the mid-20th century, focusing on its application in situations involving severe breathing difficulty or neurological depression. The research base is characterized by early comparative trials and detailed observational case series, which largely pre-date modern clinical trial standards. Studies examined patients experiencing central nervous system depression, such as those in a drug-induced coma or in post-operative recovery from older anesthetic techniques.

Researchers primarily investigated acute outcomes, including changes in respiratory rate and depth, and neurological measures like time to the return of consciousness and reflexes. Studies documented patterns of change that were measured following administered doses. These investigations were often structured to compare observations against control populations or other analeptic interventions. However, the available evidence is limited; data show patterns related to tolerability challenges, as doses required to observe a clear physiological response were associated with noticeable side effects documented in the study record.

The evidence base is overwhelmingly historical and dated, contributing to the current assessment that certainty remains low. The studies generally monitored patient responses over minutes to a few hours, meaning there is limited information for long-term outcomes or durability of effect. Furthermore, evidence quality varies across studies, and comparative evidence against current standard treatments (like modern mechanical ventilation) is lacking. Data for specific patient groups, such as children or the elderly, also remain insufficient, meaning the documented study results apply only to the populations studied in the original, historical trials.

Key Studies & References WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index - R07AB02 (Respiratory Stimulant)

Common questions about Coramine (FAQ)

---

Q: Can Coramine be taken with high blood pressure medication?

Official regulatory documents list severe hypertension (very high blood pressure) as an absolute non-eligibility condition for the medicine. The official product information also indicates a risk of enhanced stimulant effects with co-administered agents like certain Sympathomimetics (a class of stimulant drugs). Official guidance emphasizes that the use of this medicine requires careful consideration of the documented risks, particularly in patients with severe hypertension.

Q: Does Coramine affect sleep patterns?

As a Central Nervous System (CNS) stimulant, Coramine has documented neurological side effects. Official information indicates that effects like restlessness and anxiety can occur. Difficulty sleeping (insomnia) has also been cited in relation to the drug’s stimulant properties.

Q: What happens if Coramine is stopped suddenly?

According to the official product information, Coramine is typically administered as an event-driven therapy for acute, short-term symptomatic support in a supervised clinical setting. Given that the medicine is an event-driven, short-term treatment, administration is typically stopped once the immediate acute need is addressed.

Q: What are the research findings regarding Coramine's long-term use?

The research base available for Coramine is largely historical and dated, with studies primarily focused on acute patient responses that were monitored over minutes to a few hours. Consequently, there is limited information available in regulatory summaries concerning the drug's long-term outcomes or the durability of its effect.

Q: Is Coramine safe for children?

Official drug documents state that use in children and infants is highly conditional and must be approached with caution. This is because this patient population is particularly susceptible to toxic effects. Administration in children is subject to highly conditional use and requires dosage to be determined precisely based on body weight.

Q: Can Coramine cause stomach upset?

In addition to its central nervous system and cardiac effects, official literature confirms that gastrointestinal issues are associated with the drug’s use. These effects can include nausea, vomiting, and abdominal discomfort.

Q: How quickly can I expect to notice any effects from Coramine?

Coramine is designed and administered as an acute, direct-acting stimulant for short-term intervention. The official administration guidelines allow for a dose to be repeated after 20 to 30 minutes if the initial effect is insufficient, indicating that a rapid physiological response is expected.

Q: Is it normal to feel slightly dizzy after taking Coramine?

The medicine can cause documented central nervous system effects. Official warnings note that dizziness is a possible adverse reaction that can occur during use.

Q: Are there warnings about driving while using Coramine?

Due to the potential for the medicine to cause effects like dizziness, official warnings state that activities requiring concentration, such as driving and operating machinery, are to be avoided due to this potential side effect.

Q: What should I do if I miss a scheduled dose of Coramine?

The product information confirms that Coramine is administered as an event-driven therapy for acute medical support in a clinical setting, rather than on a routine or scheduled basis. As administration is event-driven for acute support rather than scheduled, the concept of a missed dose does not apply to this medicine.

Q: Is there a maximum time a person can be on Coramine?

Official regulatory use is restricted to short-term or acute symptomatic support. However, regulatory documents do not specify an exact maximum number of days or weeks that the medicine can be used.

Q: Is there a generic version of Coramine?

The active ingredient in Coramine is Nikethamide. This substance name (Nikethamide) is the International Nonproprietary Name (INN) and generic name for the substance that was historically known by the trade name Coramine.

Q: Are the side effects of Coramine dose-dependent?

Regulatory documents highlight that the risk of severe central nervous system effects is related to the amount administered. The risk of serious adverse effects, such as convulsions, is described as dose-proportional and increases significantly as the dose approaches toxic levels.

Q: Why did Coramine become less common in some countries?

The use of Coramine has generally declined in modern medical practice. This decline is officially attributed to the development of more effective and safer alternatives and because the required therapeutic dose is considered too close to the toxic level that can cause serious CNS effects like convulsions.

Q: Does Coramine have a risk of allergic reactions?

Hypersensitivity (a form of severe allergic reaction) to the drug is listed as an absolute contraindication in official documents. While considered rare, the potential for other allergic reactions is noted, with symptoms potentially including rash, itching, and difficulty breathing.

Q: Does Coramine interact with common cold or flu medicines?

The official interaction scope identifies a risk when Coramine is used with Sympathomimetics, which is a class of stimulant drugs. Some common cold and flu medicines, such as nasal decongestants, contain ingredients that belong to this class of stimulants.

Official Storage and Disposal Requirements

Official regulatory documents define specific, non-advisory requirements for the storage, handling, and disposal of Coramine (Nikethamide).

Storage Component	Requirement
Temperature	Store at room temperature, below 25 C (for final dosage forms).
Protection	Keep the product protected from light and stored in a dry place with the container tightly closed.
Handling	Keep away from heat and flame. Store the product locked up and away from children.
Disposal	Do not dispose of Coramine in household trash or empty into drains or watercourses.
Environmental	Dispose of unused or expired product and the container only via an approved waste disposal plant according to local and national regulations.

These official rules ensure product integrity and proper environmental protection.